Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.62

€1.62

-
-
-
-
 
24.05.24 / Frankfurt WKN: A3CRZT / Name: Affluent Medical Sas / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Affluent Medical Sas

sharewise wants to provide you with the best news and tools for Affluent Medical Sas, so we directly link to the best financial data sources.

News

Affluent Medical : 2023 financial results and update on clinical activities under development.
Affluent Medical : 2023 financial results and update on clinical activities under development.
Affluent Medical : 2023 financial results and update on clinical activities under development.
Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.
Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.
Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.
Affluent Medical  announces coverage initiation of its stock by TP ICAP Midcap.
Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.
Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.
Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.
Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.
Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.
Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.
Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.
Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.
Affluent Medical closes €3.5 million bridge via capital increase from key shareholders.
Affluent Medical closes €3.5 million bridge via capital increase from key shareholders.
Affluent Medical closes €3.5 million bridge via capital increase from key shareholders.
Affluent Medical : Half-year liquidity contract statement for Affluent Medical.
Affluent Medical : Half-year liquidity contract statement for Affluent Medical.
Affluent Medical : Half-year liquidity contract statement for Affluent Medical.
Affluent Medical : Pre-submission dossier for the 510(k) of medical device KaliosTM filed with FDA for review.
Affluent Medical : Pre-submission dossier for the 510(k) of medical device KaliosTM filed with FDA for review.
Affluent Medical : Pre-submission dossier for the 510(k) of medical device KaliosTM filed with FDA for review.
Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.
Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.
Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.
Affluent Medical announces coverage initiation of its stock by Portzamparc – Groupe BNP Paribas.
Affluent Medical announces coverage initiation of its stock by Portzamparc – Groupe BNP Paribas.
Affluent Medical announces coverage initiation of its stock by Portzamparc – Groupe BNP Paribas.